Stewart Kay has joined UK-based Adaptate Biotherapeutics Ltd in the new role of chief business officer (CBO). Adaptate focuses on developing antibody-based therapeutics for the modulation of gamma delta T cells, and the role has been created to drive the company’s business and corporate development activities. Mr Kay was most recently CBO at Crescendo Biologics Ltd and before that, senior director of transactions at GlaxoSmithKline Plc. He holds a BSc (Hons) in biochemistry from Swansea University and an MBA from Warwick University Business School, both in the UK.
Adaptate announced the appointment on 26 October 2020.
Copyright 2020 Evernow Publishing Ltd